News | December 14, 2023
Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Express Scripts to add Zepbound to National Preferred Formulary
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
